Clinical trials: Anti-PD-1
Myocarditis, Cardiomyopathies
JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) might induce high grade immune-related adverse events (irAEs) involving the cardio-vascular system.
- Conditions
- Myocarditis, Cardiomyopathies, Heart Diseases, Cardiovascular Diseases
- Trial name
- JOCARDITE (NCT04294771)
- Testing
- ICI
- Where
- France
- Volunteers
- 500,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
This study is researching an experimental drug called cemiplimab (called "study drug") and the combination of experimental drugs of fianlimab and cemiplimab (called "study drugs").
- Trial name
- NCT07567469
- Testing
- Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC)
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Childhood Solid Tumor
Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors
The study is a two-stage trial: 1. First stage (closed - 16 patients recruited in France): Phase I feasibility trial to evaluate the safety of the combination of Nivolumab + metronomic chemotherapy considering three possible…
- Trial name
- Metro-PD1 (NCT03585465)
- Testing
- Vinblastine, Cyclophosphamide, Capecitabine
- Where
- 11 sites in Belgium, France
- Volunteers
- 63 people
- Sponsor
- Centre Oscar Lambret
Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies
Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation
The primary objective of this study is to determine the impact of anti-checkpoint immunotherapy on type 2 inflammation via a retrospective analysis of % eosinophilia.
- Trial name
- ImmunEO (NCT04609930)
- Testing
- Anti-PD-1 or anti-PD-L1
- Where
- France
- Volunteers
- 143 people
- Sponsor
- University Hospital, Montpellier
Cancer
Study of Polyfunctionality of Anti-tumor T Lymphocytes in Cancerology: Potential Biomarker for Emerging Immunotherapies
Purposes of this study are : Characterization of polyfunctionality of anti-tumor T lymphocytes using in vitro inhibition of PD-1/PDL-1 pathway Study and comparison of polyfunctionality of anti-tumor T lymphocytes in cohorts of…
- Trial name
- POLYTCANCER (NCT02880046)
- Volunteers
- 90 people
- Sponsor
- Central Hospital, Nancy, France
Hodgkin Lymphoma
Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen
The DP regimen, low-dose decitabine combined with SHR-1210, is the new treatment for relapsed or refractory classical Hodgkin's Lymphoma.
- Trial name
- NCT04026269
- Testing
- MOAP
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Han weidong
Ewing Sarcoma, Desmoplastic Small Round Cell Tumor
EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT
This study is for people who have high-risk Ewing sarcoma (ES), or a related Ewing's family tumor, desmoplastic small round cell tumor (DSRCT).
- Trial name
- NCT07695311
- Testing
- EWSR1 immunotherapy, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Rabi Hanna
Neoplasms by Site
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or…
- Trial name
- NCT01968109
- Testing
- Relatlimab, Nivolumab, BMS-986213
- Where
- 54 sites in United States, Australia and 13 more
- Volunteers
- 1,482 people
- Sponsor
- Bristol-Myers Squibb
Hodgkin Lymphoma
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma
This is a two-stage, Phase II clinical trial for patients with relapsed or refractory Hodgkin Lymphoma. The purpose of stage I is to evaluate whether treatment with the study drug decitabine in combination with SHR-1210 is safe…
- Trial name
- NCT03250962
- Testing
- SHR-1210, Decitabine
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Chinese PLA General Hospital
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II/III Lung-MAP trial studies how well immunotherapy treatment with N-803 (ALT-803) and pembrolizumab working in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced).
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT05096663
- Testing
- Cobalamin, Dexamethasone, Docetaxel
- Where
- 350 sites in United States
- Volunteers
- 82 people
- Sponsor
- SWOG Cancer Research Network
Diffuse Large B Cell Lymphoma, Relapse/Recurrence
Decitabine and Anti-PD-1 in R/R DLBCL
Patients with relapsed/refractory diffuse large B cell lymphoma with extranodal (esp. central nervous system) involvement treated with Low-Dose Decitabine plus anti-PD-1 regimen.
- Conditions
- Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension, Central Nervous System Lymphoma
- Trial name
- NCT05816746
- Testing
- Low-Dose Decitabine plus anti-PD-1
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Advanced Melanoma
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose…
- Trial name
- NCT06264180
- Testing
- Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab
- Where
- 81 sites in United States, France and 5 more
- Volunteers
- 400 people
- Sponsor
- Replimune, Inc.
Progression-free Survival, Overall Survival
Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade osteosarcoma is dismal and unchanged over the last decades.
- Conditions
- Progression-free Survival, Overall Survival, Clinical Benefit Rate, Toxicity
- Trial name
- APFAO (NCT03359018)
- Testing
- Apatinib, SHR-1210
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- Peking University People's Hospital
Low Grade Glioma, High Grade Glioma
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
Pediatric gliomas harboring BRAF-alterations, commonly BRAFV600 mutation or KIAA1549-BRAF fusion, are currently treated with either chemotherapy or mitogen activated protein kinase (MAPK) inhibitors, such as, dabrafenib and/or…
- Trial name
- NCT06712875
- Testing
- Trametinib and Nivolumab, Dabrafenib, trametinib, nivolumab
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Thyroid Cancer
Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer
To determine the efficacy and safety of anti-PD-1 antibody Camrelizumab combined with Apatinib for neoadjuvant therapy in locally advanced thyroid cancer.
- Trial name
- NCT04612894
- Testing
- Camrelizumab and Apatinib, surgery, core needle biopsy
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Fudan University
DIPG
Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma
Diffuse pontine gliomas are incurable with currently used treatments. based on data stating that progressive tumors inhibit immune system, would try to enhance immune system activity and tumor cell killing.
- Trial name
- NCT01952769
- Testing
- MDV9300
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
Extranodal Natural Killer T Cell Lymphoma
The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of chidamide, anti-PD1 antibody, and pegaspargase versus dexamethasone, cisplatin, gemcitabine, and pegaspargase (DDGP) in…
- Trial name
- NCT06255795
- Testing
- chidamide, anti-PD1 antibody, and pegaspargase, DDGP
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Ruijin Hospital
Lymphoma, Extranodal NK-T-Cell
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.
- Trial name
- NCT06573138
- Testing
- Selinexor, anti-PD-1 antibody plus Golidocitinib
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Sarcoma
Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma
To observe the effectiveness of SHR-1210 (Camrelizumab) combined with apatinib in the treatment of unresectable sarcoma patients with chemotherapy failure.
- Trial name
- NCT04126993
- Testing
- Camrelizumab,, Apatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Melanoma (Skin)
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
This is a pilot phase 1, open-label, single center, multi-dose, dose-escalation study of BMS-936558 in combination with or without a peptide vaccine.
- Trial name
- NCT01176461
- Testing
- MART-1, NY-ESO-1, gp100:209-217(210M)
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute